KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Net Cash Flow (2016 - 2025)

TherapeuticsMD's Net Cash Flow history spans 16 years, with the latest figure at $375000.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 2105.88% year-over-year to $375000.0; the TTM value through Dec 2025 reached $2.5 million, up 109.74%, while the annual FY2025 figure was $2.5 million, 109.74% up from the prior year.
  • Net Cash Flow reached $375000.0 in Q4 2025 per TXMD's latest filing, down from $999000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $57.1 million in Q1 2021 to a low of -$140.8 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$8.6 million, with a median of -$150000.0 recorded in 2024.
  • Peak YoY movement for Net Cash Flow: skyrocketed 5515.14% in 2021, then tumbled 437.54% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $47.8 million in 2021, then plummeted by 270.95% to -$81.8 million in 2022, then soared by 96.38% to -$3.0 million in 2023, then surged by 100.57% to $17000.0 in 2024, then skyrocketed by 2105.88% to $375000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Net Cash Flow are $375000.0 (Q4 2025), $999000.0 (Q3 2025), and $381000.0 (Q2 2025).